1. Home
  2. WDS vs ALNY Comparison

WDS vs ALNY Comparison

Compare WDS & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Woodside Energy Group Limited

WDS

Woodside Energy Group Limited

HOLD

Current Price

$24.16

Market Cap

42.6B

Sector

Energy

ML Signal

HOLD

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

HOLD

Current Price

$229.95

Market Cap

38.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WDS
ALNY
Founded
1954
2002
Country
Australia
United States
Employees
N/A
115
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.6B
38.9B
IPO Year
2002
2004

Fundamental Metrics

Financial Performance
Metric
WDS
ALNY
Price
$24.16
$229.95
Analyst Decision
Strong Buy
Analyst Count
0
28
Target Price
N/A
$471.00
AVG Volume (30 Days)
586.6K
2.2M
Earning Date
02-23-2026
04-30-2026
Dividend Yield
4.50%
N/A
EPS Growth
N/A
206.88
EPS
N/A
2.71
Revenue
N/A
$1,037,418,000.00
Revenue This Year
$10.14
$52.67
Revenue Next Year
$4.92
$31.48
P/E Ratio
$11.81
$89.52
Revenue Growth
N/A
22.88
52 Week Low
$14.27
$197.81
52 Week High
$25.19
$495.55

Technical Indicators

Market Signals
Indicator
WDS
ALNY
Relative Strength Index (RSI) 65.79 43.90
Support Level $22.11 $197.81
Resistance Level $24.91 $234.00
Average True Range (ATR) 0.34 9.13
MACD 0.07 3.28
Stochastic Oscillator 91.97 64.83

Price Performance

Historical Comparison
WDS
ALNY

About WDS Woodside Energy Group Limited

Incorporated in 1954 and named after the small Victorian town of Woodside, Woodside's early exploration focus moved from Victoria's Gippsland Basin to Western Australia's Carnarvon Basin. First LNG production from the North West Shelf came in 1984. BHP Billiton and Shell each had 40% shareholdings before BHP sold out in 1994 and Shell sold down to 34%. In 2017 Shell sold its entire shareholding. Woodside is one of the most LNG-leveraged companies globally.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: